Phase 3 Clinical Trial – KYHOnline

Top News

Dr Ankit Deokar - Cornea Consultant and Chief Medical Officer - Sankara Eye Hospital - Indore

How Hazardous AQI Levels Are Threatening Eye Health: Here’s How to Keep Your Eyes Safe

Hamdard Laboratories Hosts AYUSH Convention 2025 in New Delhi

Hamdard Laboratories Hosts AYUSH Convention 2025 in New Delhi to Advance India’s Integrated Approach for Lifestyle Disease Management

Dr Aishwarya R - Consultant - Infectious Diseases - Aster Whitefield Hospital

How to live a healthy life with HIV: Doctor says don’t ignore nutrition and exercise, give up alcohol and smoking

Dr Aishwarya R - Consultant - Infectious Diseases - Aster Whitefield Hospital

World AIDS Day 2025: Signs And Symptoms Of HIV You Should Not Ignore

Apollo Hospitals Marks 27 Years of Successful Pediatric Liver Transplantation in India Organizes a workshop, training program and CME in pediatric gastroenterology and hepatology

Dr Anubbha - BHMS - Classical Homeopathy Specialist - Dr Anubbhas Homeopathy

Understanding the rise of Scrub typhus – and how to stay protected

Wellbeing Nutrition extends its portfolio into kids nutrition with the launch of Kids Superfuel

Wellbeing Nutrition extends its portfolio into kids nutrition with the launch of ‘Kids Superfuel’

Medline Academics successfully hosted its Convocation Ceremony 2025

Medline Academics & Dr. Kamini Rao Hospitals Successfully Conclude the Grand Convocation Ceremony 2025

Dr Kushal Banerjee - Dr Kalyan Banerjees Clinic

Homeopathy: A Potential Long-term Solution for Seasonal Allergies in Winter

Pharma

September 5, 2025September 7, 2025Know Your Health Team

Glenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Cancer

Glenmark Pharmaceuticals Ltd., a research-led, global pharmaceutical company, today announced the initiation of a multi-country (ex-China) Phase 3 Clinical Trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant/adjuvant setting. The Company has received approval from the Drugs Controller General of India (DCGI) […]

Back To Top